Last edition
News about "advanced solid tumours"
Harbour BioMed Secures China IND Approval for HBM7004 in Advanced Solid Tumours
NMPA clearance advances the B7H4xCD3 bispecific antibody toward clinical development, following promising preclinical efficacy and safety results and recent US FDA clearance.
Advanced Solid Tumours | 19/08/2026 | By News Bureau
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Advanced Solid Tumours | 27/07/2026 | By News Bureau | 110
CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours
CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.
Advanced Solid Tumours | 16/02/2026 | By News Bureau | 222
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Advanced Solid Tumours | 12/11/2025 | By Dineshwori | 954
SPARC Submits IND Application for SBO-154 to USFDA
Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.
Advanced Solid Tumours | 31/03/2025 | By Aishwarya | 473
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy